


Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn’s Disease

Ribonexus appoints Steven Powell as CEO

Univercells raises € 44 million in first close of its Series D

Tridek-One closes a €16 million financing round to develop first-in-class imune checkpoint agonists
